|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Galceran J, Ameijide A, Carulla M, Mateos
A, Quirós JR, Rojas D, Alemán A, Torrella A, Chico M, Vicente M, et
al: Cancer incidence in Spain, 2015. Clin Transl Oncol. 19:799–825.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zadnik V, Mihor A, Tomsic S, Zagar T, Bric
N, Lokar K and Oblak I: Impact of COVID-19 on cancer diagnosis and
menagement in Slovenia-preliminary results. Radiol Oncol.
54:329–334. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hedegaard H, Johnson RL, Garnett MF and
Thomas KE: The International Classification of Diseases, 10th
Revision, Clinical Modification. The National Center for Health
Statistics (NHCS). 36:2019.PubMed/NCBI
|
|
5
|
World Health Organization (WHO): The
Anatomical Therapeutic Chemical Classification System with Defined
Daily Doses (ATC/DDD). World Health Organization, Geneva,
Switzerland, c2018, 2018.
|
|
6
|
The 27 MedDRA system organ classes. In:
Medical Dictionary for Regulatory Activities-MedDRA. Database of
Adverse Event Notifications. Accessed July 20, 2016.
|
|
7
|
Naranjo CA, Busto U, Sellers EM, Sandor P,
Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method
for estimating the probability of adverse drug reactions. Clin
Pharmacol Ther. 30:239–245. 1981.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Castells MC, Tennant NM, Sloane DE, Hsu
FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN,
Palis RI, et al: Hypersensitivity reactions to chemotherapy:
outcomes and safety of rapid desensitization in 413 cases. J
Allergy Clin Immunol. 122:574–580. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Feliu J, Heredia-Soto V, Gironés R,
Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C and Molina-Garrido
MJ: Management of the toxicity of chemotherapy and targeted
therapies in elderly cancer patients. Clin Transl Oncol.
22:457–467. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ducasse K, Fernández JP, Salgado C,
Álvarez AM, Avilés CL, Becker A, Topelberg S, Tordecilla J, Varas
M, Villarroel M, et al: Characterization of episodes of febrile
neutropenia in children with acute myeloid leukemia and acute
lymphoblastic leukemia. Rev Chilena Infectol. 31:333–338.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Avilés-Robles M, Ojha RP, González M,
Ojeda-Diezbarroso K, Dorantes-Acosta E, Jackson BE, Johnson KM and
Caniza MA: Bloodstream infections and inpatient length of stay
among pediatric cancer patients with febrile neutropenia in Mexico
city. Am J Infect Control. 42:1235–1237. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Haile DB, Ayen WY and Tiwari P: Prevalence
and assessment of factors contributing to adverse drug reactions in
wards of a tertiary care hospital, India. Ethiop J Health Sci.
23:39–48. 2013.PubMed/NCBI
|
|
13
|
Giardina C, Cutroneo PM, Mocciaro E, Russo
GT, Mandraffino G, Basile G, Rapisarda F, Ferrara R, Spina E and
Arcoraci V: Adverse drug reactions in hospitalized patients:
Results of the FORWARD (facilitation of reporting in hospital ward)
study. Front Pharmacol. 9(350)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zopf Y, Rabe C, Neubert A, Janson C, Brune
K, Hahn EG and Dormann H: Gender-based differences in drug
prescription: Relation to adverse drug reactions. Pharmacology.
84:333–339. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hakkarainen KM, Hedna K, Petzold M and
Hägg S: Percentage of patients with preventable adverse drug
reactions and preventability of adverse drug reactions-a
meta-analysis. PLoS One. 7(e33236)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Soldin OP, Chung SH and Mattison DR: Sex
differences in drug disposition. J Biomed Biotechnol.
2011(187103)2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Khandelwal S, Bairy L, Vidyasagar M,
Chogtu B and Sharan K: Adverse drug reaction profile of cancer
patients on chemotherapy in a tertiary care hospital. Int J Pharm
Bio Sci. 6:233–244. 2015.
|
|
18
|
Creţu I, Bojincă M, Milicescu M, Cursaru
A, Șerban B, Crețu B, Iordache S, Pop CS, Cîrstoiu C and Ionescu R:
Musculoskeletal adverse reactions after immunotherapy for cancer: A
case series. Exp Ther Med. 22(1027)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tuccori M, Montagnani S,
Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M and
Blandizzi C: Adverse reactions to oncologic drugs: Spontaneous
reporting and signal detection. Expert Rev Clin Pharmacol. 8:61–75.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pearce A, Haas M, Viney R, Pearson SA,
Haywood P, Brown C and Ward R: Incidence and severity of
self-reported chemotherapy side effects in routine care: A
prospective cohort study. PLoS One. 12(e0184360)2017.PubMed/NCBI View Article : Google Scholar
|
